These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38379869)

  • 1. A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity.
    Albu DI; Wolf BJ; Qin Y; Wang X; Daniel Ulumben A; Su M; Li V; Ding E; Angel Gonzalo J; Kong J; Jadhav R; Kuklin N; Visintin A; Gong B; Schuetz TJ
    Oncoimmunology; 2024; 13(1):2316945. PubMed ID: 38379869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation.
    Muik A; Altintas I; Gieseke F; Schoedel KB; Burm SM; Toker A; Salcedo TW; Verzijl D; Eisel D; Grunwitz C; Kranz LM; Vormehr M; Satijn DPE; Diken M; Kreiter S; Sasser K; Ahmadi T; Türeci Ö; Breij ECW; Jure-Kunkel M; Sahin U
    Oncoimmunology; 2022; 11(1):2030135. PubMed ID: 35186440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models.
    Lakins MA; Koers A; Giambalvo R; Munoz-Olaya J; Hughes R; Goodman E; Marshall S; Wollerton F; Batey S; Gliddon D; Tuna M; Brewis N
    Clin Cancer Res; 2020 Aug; 26(15):4154-4167. PubMed ID: 32345647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity.
    Huang PL; Kan HT; Hsu CH; Hsieh HT; Cheng WC; Huang RY; You JJ
    J Transl Med; 2023 May; 21(1):346. PubMed ID: 37226226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity.
    Kotanides H; Li Y; Malabunga M; Carpenito C; Eastman SW; Shen Y; Wang G; Inigo I; Surguladze D; Pennello AL; Persaud K; Hindi S; Topper M; Chen X; Zhang Y; Bulaon DK; Bailey T; Lao Y; Han B; Torgerson S; Chin D; Sonyi A; Haidar JN; Novosiadly RD; Moxham CM; Plowman GD; Ludwig DL; Kalos M
    Cancer Immunol Res; 2020 Oct; 8(10):1300-1310. PubMed ID: 32873605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity.
    Kraman M; Faroudi M; Allen NL; Kmiecik K; Gliddon D; Seal C; Koers A; Wydro MM; Batey S; Winnewisser J; Young L; Tuna M; Doody J; Morrow M; Brewis N
    Clin Cancer Res; 2020 Jul; 26(13):3333-3344. PubMed ID: 32299814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity.
    Jiang H; Ni H; Zhang P; Guo X; Wu M; Shen H; Wang J; Wu W; Wu Z; Ding J; Tang R; Zhou S; Chen B; Yu M; Jing H; Liu J
    Oncoimmunology; 2021; 10(1):1943180. PubMed ID: 34239776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity.
    Cheng LS; Zhu M; Gao Y; Liu WT; Yin W; Zhou P; Zhu Z; Niu L; Zeng X; Zhang D; Fang Q; Wang F; Zhao Q; Zhang Y; Shen G
    Cell Mol Biol Lett; 2023 May; 28(1):47. PubMed ID: 37259060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4.
    Hao S; Xu S; Li L; Li Y; Zhao M; Chen J; Zhu S; Xie Y; Jiang H; Zhu J; Wu M
    BMC Cancer; 2022 Oct; 22(1):1092. PubMed ID: 36284271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy.
    Vitale LA; He LZ; Thomas LJ; Wasiuk A; O'Neill T; Widger J; Crocker A; Mills-Chen L; Forsberg E; Weidlick J; Patterson C; Hammond RA; Boyer J; Sisson C; Alvarado D; Goldstein J; Marsh HC; Keler T
    Cancer Immunol Immunother; 2020 Oct; 69(10):2125-2137. PubMed ID: 32451681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation.
    Sung E; Ko M; Won JY; Jo Y; Park E; Kim H; Choi E; Jung UJ; Jeon J; Kim Y; Ahn H; Choi DS; Choi S; Hong Y; Park H; Lee H; Son YG; Park K; Won J; Oh SJ; Lee S; Kim KP; Yoo C; Song HK; Jin HS; Jung J; Park Y
    Mol Ther; 2022 Aug; 30(8):2800-2816. PubMed ID: 35526096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
    Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
    Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade.
    Jeong S; Park E; Kim HD; Sung E; Kim H; Jeon J; Kim Y; Jung UJ; Son YG; Hong Y; Lee H; Lee S; Lim Y; Won J; Jeon M; Hwang S; Fang L; Jiang W; Wang Z; Shin EC; Park SH; Jung J
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34230109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
    Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel Bispecific Antibody with PD-L1-assisted OX40 Activation for Cancer Treatment.
    Kuang Z; Pu P; Wu M; Wu Z; Wang L; Li Y; Zhang S; Jing H; Wu W; Chen B; Liu J
    Mol Cancer Ther; 2020 Dec; 19(12):2564-2574. PubMed ID: 32999045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PD-L1/4-1BB Bispecific Antibody-Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner.
    Peper-Gabriel JK; Pavlidou M; Pattarini L; Morales-Kastresana A; Jaquin TJ; Gallou C; Hansbauer EM; Richter M; Lelievre H; Scholer-Dahirel A; Bossenmaier B; Sancerne C; Riviere M; Grandclaudon M; Zettl M; Bel Aiba RS; Rothe C; Blanc V; Olwill SA
    Clin Cancer Res; 2022 Aug; 28(15):3387-3399. PubMed ID: 35121624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response.
    Rubio-Pérez L; Lázaro-Gorines R; Harwood SL; Compte M; Navarro R; Tapia-Galisteo A; Bonet J; Blanco B; Lykkemark S; Ramírez-Fernández Á; Ferreras-Gutiérrez M; Domínguez-Alonso C; Díez-Alonso L; Segura-Tudela A; Hangiu O; Erce-Llamazares A; Blanco FJ; Santos C; Rodríguez-Peralto JL; Sanz L; Álvarez-Vallina L
    Oncoimmunology; 2023; 12(1):2205336. PubMed ID: 37114242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment.
    Wang R; Zhang C; Cao Y; Wang J; Jiao S; Zhang J; Wang M; Tang P; Ouyang Z; Liang W; Mao Y; Wang A; Li G; Zhang J; Wang M; Wang S; Gui X
    Theranostics; 2023; 13(1):148-160. PubMed ID: 36593962
    [No Abstract]   [Full Text] [Related]  

  • 19. The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1.
    Yi M; Zhang J; Li A; Niu M; Yan Y; Jiao Y; Luo S; Zhou P; Wu K
    J Hematol Oncol; 2021 Feb; 14(1):27. PubMed ID: 33593403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling.
    Li T; Niu M; Zhou J; Wu K; Yi M
    Cell Commun Signal; 2024 Mar; 22(1):179. PubMed ID: 38475778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.